ALR Technologies Inc.

ALR Technologies Inc., a data management company, develops diabetes care solutions for human and animal health in the United States. It provides Diabetes Management System, a comprehensive approach to diabetes care consisting of data collection, predictive A1C, insulin dosage adjustment suggestions, performance tracking, remote monitoring, and diabetes test supplies. The company also offers Continuous Glucose Monitoring (CGM), a medical device that is worn on the body of a diabetic subject for blood sugar readings; and GluCurve Pet CGM to address an unmet need in diabetes care for felines and canines used by veterinarians in animal health, as well as Prediabetes System, which provides patients with educational videos and supplemental content formatted for mobile devices and a private online community to discuss disease management. Its primary business markets are health care providers, the providers of health insurance, and the providers of disease and case management services, including the home care industry. The company was formerly known as Mo Betta Corp. and changed its name to ALR Technologies Inc. in December 1998. ALR Technologies Inc. was incorporated in 1987 and is based in Richmond, Virginia. ALR Technologies Inc. operates as a subsidiary of ALR Technologies SG Ltd.

ALR Technologies Inc. trades as ALRTF on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

ALR Technologies Inc. can be compared against peers such as CelLBxHealth plc, Biotricity, Inc., EOM Pharmaceuticals Holdings, Inc., Algorae Pharmaceuticals Limited, Numinus Wellness Inc., OpGen, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $11.42M, beta of 2.41, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ALRTF currently shows total debt of N/A and beta of 2.41. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.alrt.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.